EU-OPENSCREEN-DRIVE Chemoproteomics and MS Imaging Call 2 – Proposal Guidelines

Access: this EU-OPENSCREEN-DRIVE Chemoproteomics and MS Imaging Call 2 offers funding to enable transnational access to chemical proteomics and compound disposition study facilities supporting at least 3 user projects.

Eligibility:

- Applicants may come from academia or industry (including SMEs).
- Applicants may be working in an institution of a European Member State or Associated country. Up to one (1) project will be open to applicants from outside Europe.
- User access is transnational only. Users are not allowed to access facility(ies) in their home country.
- Principal investigators and members of their research groups from EU-OPENSCREEN-DRIVE beneficiaries are not eligible to apply.
- Applicants commit to have legal and ethical consent regarding their research, their samples and/ or their data prior to submitting their application.
- Applicants must agree to comply with the access, IP and dissemination policies described in the statutes of EU-OPENSCREEN ERIC.
- Applicants must agree to comply with EU-OPENSCREEN ERIC/ EU-OPENSCREEN-DRIVE privacy policy and terms of submission.
- If you have any doubt or question relating to the eligibility criteria for this call please contact us at help-desk-open-call@eu-openscreen.eu (indicating "EU-OPENSCREEN-DRIVE Chemoproteomics and MSI Call 2" within the subject).

Publication: Open access (gold or green) is required for any publication of access results. EU-OPENSCREEN-DRIVE funding must be clearly acknowledged by: "*This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 823893*."

Open access EU-OS chemical biology database (ECBD): Data will be deposited with a flexible privacy model for rapid and safe dissemination and exploitation. Users stay owner of their data. The optional hold period will be 36 months for data publication. There will be high standards of security and traceability of IP (citable indexing of data points (EUOS, DOI or URL) and links to originator labs for primary raw unprocessed data. Data are disseminated according to the FAIR data principles (i.e., Findable, Accessible, Interoperable and Re-usable), allowing communities across academia, SMEs and industry to benefit from EU-OPENSCREEN's activities. Please read more about our EU-OPENSCREEN ERIC database on the link: https://www.eu-openscreen.eu/services/database.html.

Proposal and deadlines: Applicants will submit their proposals via EU-OPENSCREEN-DRIVE website, by connecting to the ARIA online submission platform. The online proposal submission will be open **until May 17th, 2021,16:00 CET**. Applicants will be notified about acceptance or rejection of their proposal within 12 weeks after the closure of the EU-OPENSCREEN-DRIVE Chemoproteomics and MS Imaging Call 2.

ARIA: The ARIA application platform for EU-OPENSCREEN-DRIVE is handled by Instruct-ERIC. Although potential EU-OPENSCREEN-DRIVE users are requested to register with the ARIA system, the application, review, and reporting process will be handled by EU-OPENSCREEN-DRIVE.

Application step by step:

Click on "Begin a new proposal" and follow the instructions.

*Required fields.

1. **Proposal Details**

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893

*Research project title:** provide a title for your project.

Complete the following application form with details of your proposed research. Please notice that instructions/ help text are available for each question pointing the mouse cursor on the question mark related to the field of interest.

Project overview, significance and objectives:* provide a detailed overview of the project and report on its significance and objectives including the rationale and the expected impact of the research. (max length 5000 characters)

*Describe the added value of using chemoproteomics approaches for the proposed research:** please include outcome expectations. (max length 5000 characters)

Relevant publications:* please include up to 5 relevant publications.

Description of the scientific work:* please give a detailed description of up-to-date research and planned follow-up experiments. If possible, disclose structure of compound of interest for further feasibility assessment. (max length 5000 characters)

Upload files here (if any). Choose file (maximum file size: 10 MB)

*Please provide a brief description of your/ PI's CV:** please include in this section a brief overview of your education, professional background, and expertise that supports the proposed research. (max length 5000 characters)

*Is a cellular or organismal activity in the low µM range confirmed?** If yes, please give details. If no, please comment (max length 3000 characters)

*Have the preliminary Structure Activity Relationships (SAR) been identified? ** If yes, please give details including information on pan-assay interference (PAIN) analysis of the structure (add literature reference if available), availability of structurally similar active and non-active compounds, *etc.* If no, please comment (max length 3000 characters)

*Is the SAR-informed synthesis of linker derivatives for functional immobilization in place? ** Please comment your answer (max length 3000 characters)

*Indicate the amount of compound available for the project.** (max length 3000 characters)

*Indicate if a (bio)synthetic route is available (preferentially bearing functional groups for further modification, which would not interfere with activity):** please report source/ reference of synthetic protocol and provide information about reaction scalability: <1 mg, 1-10 mg, >10 mg (max length 5000 characters)

*Indicate the purity of the compound (is it > 95%?)** (max length 3000 characters)

*Indicate which methods have been used for purity determination.** (max length 3000 characters)

*Comment on biological material/ model to be used in the project and your capacity to provide it (e.g. indicate the amount of lysates or whole cells, cellular compartments, tissues of any given organism available for the project):** please comment. (max length 5000 characters) – 17*Describe assays (e.g. biochemical, phenotypic) which have been performed with the compound of interest*:* please comment. (max length 5000 characters)

Are in-vitro ADME data available? (e.g. permeability, plasma protein binding, metabolic stability):* please comment on availability of compound in-vitro data. (max length 5000 characters)

Are in-vivo pharmacokinetic data available (e.g. half-life, bioavailability, maximum tolerated dose (MTD), etc)? – this field is mandatory for MSI projects. Please comment on availability of compound pharmacological data if applying for compound disposition studies. (max length 5000 characters)

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893

If available, provide information on preliminary hypotheses around mode of action or target protein for compound to be tested: please comment. (max length 5000 characters)

*Please comment on the innovative potential of proposed research.** (max length 5000 characters)

*Please describe gender aspects of the proposed research:** please address the gender aspects both, in the group/ team and in the research content. (max length 5000 characters)

*Ethics: does the activity proposed within this call involve research using human cells or tissues?** If yes, please specify. (max length 3000 characters)

Ethics: does the research activity proposed within this call involve research on animals? * If yes, please specify. (max length 3000 characters)

Please upload any additional document relevant for the evaluation of this proposal. Choose file (maximum file size: 10 MB)

Additional comments. Please add any additional relevant comment and/ or information. (max length 3000 characters)

User statement:

☐ *I agree to be the principal investigator of the submitted project as it is described in the present application.*

☐ *I confirm that all relevant authorizations, declarations and accreditation from competent authority(ies) have been obtained in order to process the above mentioned samples and data through EU-OPENSCREEN-DRIVE, for the requested purposes, in full compliance with the applicable EU and National laws.**

☐ *All publications resulting or including data obtained through EU-OPENSCREEN-DRIVE will be published under open access.**

☐ *Legal requirements for exporting/ importing materials to/ from other countries have been met.**

Do you agree that EU-OPENSCREEN-DRIVE partners exploit general information of your project for outreach and reporting purposes (respecting confidentiality of project specifics)?* In case that you do not agree, please give your explanation in the comment section.

If no, please comment (max length 3000 characters)

Other:

How did you hear about the EU-OPENSCREEN-DRIVE transnational access calls? Please select one or multiple options from the drop-down menu.

☐EU-OPENSCREEN website; ☐EU-OPENSCREEN-DRIVE website; ☐EU-OPENSCREEN newsletter; ☐NKS newsletter; ☐ other newsletters (please specify in the box below); ☐via institutional email; ☐via other European research infrastructures (e.g. INFRAFRONTIER, Instruct, BBMRI, Euro-Bioimaging, etc); ☐at conferences/ meetings/ scientific events (please specify in the text box below); ☐E-alert Nature Methods; ☐LifeScience RI webpage; ☐Twitter; ☐LinkedIn; ☐other social media channels (please specify in the text box below); ☐other (please specify).

2. Your Research Team

Choose which local researchers from your lab will be involved in the project.

Principal Investigator: The Principal Investigator (PI) is a scientist eligible by their institution to apply for grants. If you, the applicant, are not the selected PI the system will send an automatic message

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893

for authorization of the proposal. Please note that the user profile will be the reviewer's main source of information about the PI, applicant and team.

Note: If you select a Principal Investigator other than yourself they will be contacted by email to verify this submission.

Home Lab Colleagues: in addition to the applicant, please indicate other members of your home institution that will be part of the research project. Only scientists mentioned in this section will be eligible to access facilities (if applicable) if the proposal is approved. Please note that the user profile will be the reviewer's main source of information about the applicant and the team.

Note: Applicants (including PI and home lab colleagues which are mentioned in the proposal) should register for an ARIA account prior to the submission of the proposal or login directly if they are already registered with an ARIA account. Once registered, the applicants are required to follow ARIA instructions. Please note that the user profile will be the reviewer's main source of information about the applicant and the team. Please make sure to provide adequate information for evaluation.

3. Exclude Reviewers

Feel free to exclude reviewers that may have a conflict of interest.

List of Excluded Reviewers: specify any reviewers you would like to exclude because of conflicts of interest.

4. Confirm Proposal

Review the information you have entered and submit your proposal for moderation and review.

5. Accept terms and conditions of submission

Accept terms and conditions of the access routes you have selected.
Terms and conditions are available here.

6. Proposal submitted

Your application to EU-OPENSCREEN-DRIVE Chemoproteomics and MS Imaging Call 2 has been submitted successfully. A moderator will soon be assigned to choose relevant reviewers, who will score your proposal and give feedback as to potential changes to strengthen the proposal. Please make a note of your proposal's PID number as it will be required if you need any future support or information relating to this submission. You can view all of your submitted proposals in your dashboard and view and track this proposal by selecting 'View Proposal' from your dashboard.

This project has received funding from the European Union´s Horizon 2020 research and innovation programme under the grant agreement No. 823893